The following Table is missing from abstract number P210, Pharmacological characterisation of the GPCR mas, in the Selected Abstracts from Pharmacology 2018:
| Compound | Reported activity | pEC50 | Maximal response* | n |
|---|---|---|---|---|
| SB‐444827 | — | 5.97 ± 0.10 | 77.6 ± 8.5 | 5 |
| d‐Pro2‐Spantide I | — | 5.96 ± 0.03 | 100 | 16 |
| Neuropeptide FF | Agonist | 4.48 ± 0.10 | 103.5 ± 7.9 | 6 |
| CGEN‐856S | Agonist | 5.22 ± 0.04 | 69.8 ± 5.6 | 6 |
| MBP7 | Agonist | Inactive | 5 | |
| ANG(1‐7) | Agonist | Inactive | 8 | |
| AR234960 isomer a | Agonist | 6.34 ± 0.04 | 123.2 ± 7.2 | 4 |
| AR234960 isomer b | Agonist | 6.13 ± 0.04 | 113.8 ± 9.9 | 4 |
| AVE0991 | Agonist | Inactive | 5 | |
| AR244555 | Inverse agonist | 5.73 ± 0.04 | −63.3 ± 6.3 | 6 |
| A779 | Antagonist | Inactive | 5 |
*
% of response to d‐Pro2‐Spantide I; — previously uncharacterised.
REFERENCE
- (2019). Selected Abstracts from Pharmacology 2018. British Journal of Pharmacology, 176(16): 2977–3081. 10.1111/bph.14681 [DOI] [Google Scholar]